HHHalla Helgadottir

Halla Helgadottir

*This is an algorithmically generated author record based on publicly available information.

Halla Helgadottir has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mining Association Rules From a Multimodal Dataset of a Digital Therapeutics Application for Sleep Improvement Through a Healthy Lifestyle: Quantitative Study.

    by Luka Biedebach, Katrín Ýr Friðgeirsdóttir, Camilla Carpinelli, Ari Páll Isberg, Halla Helgadóttir, Erna Sif Arnardóttir, Jose M Saavedra, Anna Sigridur Islind

    The demand for sleep interventions is high and steadily growing. Digital therapeutics (DTx) can help individuals improve their sleep remotely, over an extended period, and with less effort from medical professionals. Obstructive sleep apnea (OSA), one of the most prevalent and consequential sleep disorders, can be treated with health-supporting behavior changes, such as physical exercise and weight loss, and, therefore, acts as a promising application for DTx. The study aimed to analyze a digital intervention from both medical and technological perspectives by moving beyond clinical markers and exploring more deeply how the DTx application was used. This study aimed to propose a novel way in which association rules can function as an exploratory tool to analyze the sleep, behavior, and engagement of participants with the DTx application on a day-to-day level. A lifestyle intervention study (N=192) targeted at adults with mild-to-moderate OSA aimed to reduce their OSA severity using a DTx application and an exercise program over a study period of 12 weeks. The participants' OSA severity was assessed through polysomnography at the beginning and at the end of the study period, and the participants tracked their sleep with a digital sleep diary and a smartwatch over the course of the entire study. The DTx application provided data on when and how the participants pursued the proposed lifestyle interventions. These heterogeneous data sources were combined into one multimodal dataset, which was explored through descriptive statistics. Ultimately, the data were turned into a transaction-based format, and association rules were derived using the Apriori algorithm. Analyzing the participants' interaction with the application revealed the lifestyle interventions they pursued and how their behavior and sleep patterns changed over time. The Apriori algorithm generated a set of association rules with lift and confidence scores that were significantly higher than those for the co-occurrence of items through random chance. The rules show co-occurrence of missions and items from the sleep diary, as well as items derived from the watch measurements. The study showed the richness of the various data sources provided by a digital intervention using wearables and how they can be used to get an in-depth understanding of the study. The generated association rules showed the presence of significant co-occurrences across the different data modalities and highlighted their effectiveness as an exploratory tool for multimodal health data.

  • Open Access

    Engagement, Retention, and Acceptability in a Digital Health Program for Atopic Dermatitis: Prospective Interventional Study

    by Sigrídur Lára Gudmundsdóttir, Tommaso Ballarini, María L Ámundadóttir, Judit Mészáros, Jenna Huld Eysteinsdottir, Ragna H Thorleifsdottir, Sigrídur K Hrafnkelsdóttir, Halla Helgadottir, Saemundur Oddsson, Jonathan I Silverberg

    Background: Patients with atopic dermatitis can experience chronic eczema with pruritus, skin pain, sleep problems, anxiety, and other problems that reduce their quality of life (QoL). Current treatments aim to improve these symptoms and reduce inflammation, but poor treatment adherence and disease understanding are key concerns in the long-term management of atopic dermatitis. Digital therapeutics can help with these and support patients toward a healthier lifestyle to improve their overall QoL. Objective: The aim of the study is to test the feasibility of a digital health program tailored for atopic dermatitis through program engagement, retention, and acceptability. Methods: Adults with atopic dermatitis were recruited in Iceland for a 6-week digital health program delivered through a smartphone app. Key components of the digital program were disease and trigger education; medication reminders; patient-reported outcomes (PROs) on energy levels, stress levels, and quality of sleep (referred to as QoL PROs); atopic dermatitis symptom PROs; guided meditation; and healthy lifestyle coaching. The primary outcome was program feasibility, as assessed by in-app retention and engagement. User satisfaction was assessed by the mHealth (ie, mobile health) App Usability Questionnaire (MAUQ). Results: A total of 21 patients were recruited (17 female, mean age 31 years), 20 (95%) completed the program. On average, users were active in the app 6.5 days per week and completed 8.2 missions per day. The education content, medication reminders, and PROs had high user engagement and retention; all users who were exposed to the QoL PROs (n=17) interacted with these, and 20/21 (95%) users were continuously engaged with the education missions, medication missions, and symptom PROs. Continued engagement with the step counter and mind missions among exposed users was lower (17/21 and 13/20 participants, respectively). Medication reminder and education task completion remained high over time (at least 18/20, 90%), but weekly interactions declined. All assigned users completed atopic dermatitis symptom PROs on weeks 1-5 and only one did not do so on week 6; the reported number and total severity of atopic dermatitis symptoms reduced during the program. Regarding the QoL PROs, 16/17 (94%) and 14/17 (82%) users interacted with these at least 3 times in the first and last week of the program, respectively, and all reported improvements over time. User satisfaction was high with a total score of 6.2/7. Conclusions: We found high overall engagement and retention in a targeted digital health program among patients with atopic dermatitis, as well as high compliance with missions relating to medication reminders, patient education, and PROs. Symptom number and severity were reduced, and QoL PROs improved over time. We conclude that a digital health program is feasible and may provide added benefits for patients with atopic dermatitis, including the tracking and improvement of atopic dermatitis symptoms.


  • Open Access

    Evaluating the Feasibility of a Digital Therapeutic Program for Patients With Cancer During Active Treatment: Pre-Post Interventional Study

    by G Haukur Gudmundsson, Judit Mészáros, Ágústa E Björnsdóttir, María L Ámundadóttir, Gudrun E Thorvardardottir, Erna Magnusdottir, Halla Helgadottir, Saemundur Oddsson

    Background: Increasing evidence shows that lifestyle interventions can improve the symptoms, quality of life (QoL), and even overall survival of patients with cancer. Digital therapeutics (DTx) can help implement behavioral modifications and empower patients through education, lifestyle support, and remote symptom monitoring. Objective: We aimed to test the feasibility of a DTx program for patients with cancer, as measured by engagement, retention, and acceptability. In addition, we explored the effects of the program on cancer-related QoL. Methods: We conducted a 4-week single-arm trial in Iceland, where DTx was delivered through a smartphone app. The intervention consisted of patient education about mindfulness, sleep, stress, and nutrition; lifestyle coaching; and the completion of daily missions for tracking physical activity and exercise, reporting patient-reported outcomes (PROs), practicing mindfulness, and logging healthy food intake. Information on program engagement and retention, step goal attainment, as well as PROs were collected throughout the study. QoL was measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 at baseline and follow-up. Results: In total, 30 patients with cancer undergoing active therapy were enrolled, and 29 registered in the app (23 female, 18 with breast cancer; mean age 52.6, SD 11.5 years). Overall, 97% (28/29) of participants were active in 3 of the 4 weeks and completed the pre- and postprogram questionnaires. The weekly active days (median) were 6.8 (IQR 5.8-6.8), and 72% (21/29) of participants were active at least 5 days a week. Users interacted with the app on average 7.7 (SD 1.9) times per day. On week 1, all 29 participants used the step counter and logged an average of 20,306 steps; 21 (72%) participants reached their step goals of at least 3000 steps per day. On week 4, of the 28 active users, 27 (96%) were still logging their steps, with 19 (68%) reaching their step goals. Of the 28 participants who completed the satisfaction questionnaire, 25 (89%) were likely to recommend the program, 23 (82%) said the program helped them deal with the disease, and 24 (86%) said it helped them remember their medication. QoL assessment showed that the average global health status, functioning, and symptom burden remained stable from baseline to follow-up. In all, 50% (14/28) of participants reported less pain, and the average pain score decreased from 31 (SD 20.1) to 22.6 (SD 23.2; P=.16). There was no significant change in PROs on the quality of sleep, energy, and stress levels from the first to the last week. Conclusions: The high retention, engagement, and acceptability found in this study demonstrate that multidisciplinary DTx is feasible for patients with cancer. A longer, full-scale randomized controlled trial is currently being planned to evaluate the efficacy of the intervention.


  • Open Access

    Engagement, Retention, and Acceptability in a Digital Health Program for Atopic Dermatitis: Prospective Interventional Study (Preprint)

    by Sigrídur Lára Gudmundsdóttir, Tommaso Ballarini, María L Ámundadóttir, Judit Mészáros, Jenna Huld Eysteinsdottir, Ragna H Thorleifsdottir, Sigrídur K Hrafnkelsdóttir, Halla Helgadottir, Saemundur Oddsson, Jonathan I Silverberg

    BACKGROUND Patients with atopic dermatitis can experience chronic eczema with pruritus, skin pain, sleep problems, anxiety, and other problems that reduce their quality of life (QoL). Current treatments aim to improve these symptoms and reduce inflammation, but poor treatment adherence and disease understanding are key concerns in the long-term management of atopic dermatitis. Digital therapeutics can help with these and support patients toward a healthier lifestyle to improve their overall QoL. OBJECTIVE The aim of the study is to test the feasibility of a digital health program tailored for atopic dermatitis through program engagement, retention, and acceptability. METHODS Adults with atopic dermatitis were recruited in Iceland for a 6-week digital health program delivered through a smartphone app. Key components of the digital program were disease and trigger education; medication reminders; patient-reported outcomes (PROs) on energy levels, stress levels, and quality of sleep (referred to as QoL PROs); atopic dermatitis symptom PROs; guided meditation; and healthy lifestyle coaching. The primary outcome was program feasibility, as assessed by in-app retention and engagement. User satisfaction was assessed by the mHealth (ie, mobile health) App Usability Questionnaire (MAUQ). RESULTS A total of 21 patients were recruited (17 female, mean age 31 years), 20 (95%) completed the program. On average, users were active in the app 6.5 days per week and completed 8.2 missions per day. The education content, medication reminders, and PROs had high user engagement and retention; all users who were exposed to the QoL PROs (n=17) interacted with these, and 20/21 (95%) users were continuously engaged with the education missions, medication missions, and symptom PROs. Continued engagement with the step counter and mind missions among exposed users was lower (17/21 and 13/20 participants, respectively). Medication reminder and education task completion remained high over time (at least 18/20, 90%), but weekly interactions declined. All assigned users completed atopic dermatitis symptom PROs on weeks 1-5 and only one did not do so on week 6; the reported number and total severity of atopic dermatitis symptoms reduced during the program. Regarding the QoL PROs, 16/17 (94%) and 14/17 (82%) users interacted with these at least 3 times in the first and last week of the program, respectively, and all reported improvements over time. User satisfaction was high with a total score of 6.2/7. CONCLUSIONS We found high overall engagement and retention in a targeted digital health program among patients with atopic dermatitis, as well as high compliance with missions relating to medication reminders, patient education, and PROs. Symptom number and severity were reduced, and QoL PROs improved over time. We conclude that a digital health program is feasible and may provide added benefits for patients with atopic dermatitis, including the tracking and improvement of atopic dermatitis symptoms. CLINICALTRIAL


  • Open Access

    Supporting Cancer Patients on Their Treatment Journey Towards Self-Efficacy: Usability Pilot Study of a Digital Therapeutic Solution (Preprint)

    by G. Haukur Gudmunsson, Judit Mészáros, Ágústa Björnsdóttir, María L. Ámundadóttir, Gudrun E. Thorvardardottir, Erna Magnusdottir, Halla Helgadottir, Saemundur Oddson

    BACKGROUND Digital lifestyle interventions can help cancer survivors better manage their disease through improved lifestyle choices. OBJECTIVE Our aim was to test the feasibility of a digital therapeutic (DTx) program for cancer patients, as measured by engagement, retention, and acceptability. We additionally explored the effects of the program on cancer-related quality of life. METHODS A four-week-long, single-arm trial was conducted in Iceland where the DTx was delivered through a smartphone app. The intervention consisted of completing daily missions (e.g., food logging, activity tracking, surveys) and receiving educational content about mindfulness, sleep, stress, and nutrition. Usage information such as engagement, retention, and step goal attainment, as well as patient-reported outcomes about energy, stress and quality of sleep were collected throughout the study. Cancer-specific quality of life using the EORTC QLQ-C30 questionnaire, as well as cardiovascular fitness and body composition were measured at baseline and follow-up. RESULTS Thirty cancer patients in active treatment were enrolled and 29 registered in the program (79% female, with mean age of 52.6 years, 62% with breast cancer). All 29 participants were active at least three out of four weeks, and 28 (97%) completed the pre- and post- program questionnaires. 72% were highly engaged, the median number of weekly active days were 6.8 (IQR: 5.8, 6.8), and mean daily mission interactions were 7.7 (SD = 1.9). On week one, all 29 participants used the step counter, and 72% reached their step goals; most of these individuals (n = 27) were still using the step counter on week four, with 70% reaching their step goals. The DTx had high acceptability, as 89% of participants said they were likely to recommend it, and 82% said the program helped them deal with the disease. Quality of life (QoL) assessment showed that global health status, functioning and symptom burden remained stable from baseline to follow-up. The largest improvement was observed in pain scores, which decreased from 31 (SD = 20.1) to 22.6 (SD = 23.2) (P= .16). CONCLUSIONS The high retention, engagement and acceptability found in this study demonstrate that a multidisciplinary DTx is feasible for cancer patients. A longer, full-scale randomized controlled trial (RCT) is currently being planned to evaluate the efficacy of the intervention.